Table 1 |
|||
|
Experimental groups.* |
|||
| Groups |
Infection (P. aeruginosa) |
Intervention |
n |
|
|
|||
| Control |
None |
3 |
|
|
|
|||
| Co-instillation |
Antibodies were premixed with PA103 |
||
|
|
|||
| Control IgG |
PA103 (5 × 107 CFU), IT |
Control IgG (IgG2b), 4 mg/ml IT |
3 |
| Rab anti-PcrV |
PA103 (5 × 107 CFU), IT |
Polyclonal anti-PcrV IgG, 4 mg/ml IT |
3 |
| Mab166 |
PA103 (5 × 107 CFU), IT |
Monoclonal Mab166, 4 mg/ml IT |
3 |
|
|
|||
| Therapeutic |
Antibodies were intratracehally instilled 1 h after the instillation of PA103 |
||
|
|
|||
| w/o IgG |
PA103 (5 × 107 CFU), IT |
Phosphate-buffered saline |
5 |
| Rab anti-PcrV |
PA103 (5 × 107 CFU), IT |
Polyclonal anti-PcrV IgG, 4 mg/ml IT |
3 |
| Mab166 |
PA103 (5 × 107 CFU), IT |
Monoclonal Mab166, 4 mg/ml IT |
5 |
| Mab166 Fab |
PA103 (5 × 107 CFU), IT |
Fab fragments of Mab166, 4 mg/ml IT |
3 |
|
|
|||
|
*IT: Intratracheal administration |
|||
|
Faure et al. Journal of Immune Based Therapies and Vaccines 2003 1:2 doi:10.1186/1476-8518-1-2 |
|||
